Dr. Manish Shah on the METGastric Study

Manish A. Shah, MD
Published: Thursday, Jun 04, 2015



Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

The METGastric study examined onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. Previous data demonstrated that onartuzumab has activity against the MET receptor. Onartuzumab is considered a novel agent, Shah says, because it is a single chain of the IgG molecule that inhibits the MET pathway and the HGF binding.

Patients were randomized to receive either mFOLFOX6 or mFOLFOX6 combined with onartuzumab. The study ended prematurely due to lack of efficacy, Shah says.



Manish A. Shah, MD, medical oncology, NewYork-Presbyterian/Weill Cornell, discusses the METGastric study.

The METGastric study examined onartuzumab plus mFOLFOX6 in patients with metastatic HER2-negative and MET-positive adenocarcinoma of the stomach or gastroesophageal junction. Previous data demonstrated that onartuzumab has activity against the MET receptor. Onartuzumab is considered a novel agent, Shah says, because it is a single chain of the IgG molecule that inhibits the MET pathway and the HGF binding.

Patients were randomized to receive either mFOLFOX6 or mFOLFOX6 combined with onartuzumab. The study ended prematurely due to lack of efficacy, Shah says.




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: CDK4/6 Inhibitors With the Experts: The Role of Emerging Agents for the Management of Metastatic Breast CancerMay 30, 20182.0
Medical Crossfire®: Clinical Updates on PARP Inhibition and its Evolving Use in the Treatment of CancersMay 30, 20181.5
Publication Bottom Border
Border Publication
x